Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Comment by dt_coreon Apr 27, 2013 9:17am
87 Views
Post# 21309510

RE: RE: RE: Q1 CC

RE: RE: RE: Q1 CC

I realize that the call is on a Weds, but the notification about the call was sent to investors yesterday after the market close. It's poor messaging.

 

The company historically has always kept an investor presentation on their website, generally outlining the company, its strategy, and vision/goals. The presentation was not for the investor calls but rather a general ongoing communication about the company to both existing and prospective shareholders. This presentation has not been updated since Aug-12 and no longer appears on the Agjunction website. In fact the investor section of the website did not update 2012 filings when sedar did. That's poor messging.

 

I agree that press releases for the sake of them can be noise. I do not tihnk that the release of STX is just noise. I do not think that fullfilling commitments about a February operational update is just noise. I do not think providing investors colour on the progress of the JV with Claas is noise. etc etc

 

I agree we need evidence of results. That's not what I'm griping about. But if they want to attract investors to the story they'll need to do a much better job of communicating with them. Hence, it may be time for new IR leadership to coincide with the reorg of the business.

Bullboard Posts